A 32-Week Randomized Comparison of Stepwise Insulin Intensification of Biphasic Insulin Aspart (BIAsp 30) Versus Basal–Bolus Therapy in Insulin-Naïve Patients with Type 2 Diabetes

被引：0

作者：

Sultan Linjawi

Byung-Wan Lee

Ömür Tabak

Susanna Lövdahl

Shanti Werther

Salahedeen Abusnana

机构：

[1] Coffs Endocrine and Diabetes Service,Division of Endocrinology and Metabolism, Department of Internal Medicine

[2] Yonsei University College of Medicine,Internal Medicine Clinic

[3] Ministry of Health Istanbul Kanuni Sultan Suleyman Training and Research Hospital,undefined

[4] Novo Nordisk A/S,undefined

[5] Rashid Center for Diabetes and Research,undefined

来源：

Diabetes Therapy | 2018年 / 9卷

关键词：

Basal–bolus; BIAsp 30; Stepwise insulin intensification; Type 2 diabetes;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1 / 11

页数：10

共 50 条

[31] Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes
Hermansen, K
Fontaine, P
Kukolja, KK
Peterkova, V
Leth, G
Gall, MA
DIABETOLOGIA, 2004, 47 (04) : 622 - 629
[32] GLYCAEMIC CONTROL AND INSULIN UTILIZATION IN UK PATIENTS WITH TYPE 2 DIABETES INITIATED ON EITHER BIPHASIC INSULIN ASPART 30 OR BIPHASIC HUMAN INSULIN 30
Fakhoury, W.
Richter, H.
Christensen, T.
Thomsen, T. L.
Irwin, D.
Anderson, P.
VALUE IN HEALTH, 2010, 13 (03) : A55 - A55
[33] Lilly Insulin Glargine Versus Lantus® in Insulin-Naïve and Insulin-Treated Adults with Type 2 Diabetes: A Randomized, Controlled Trial (ELEMENT 5)
Robyn K. Pollom
Liza L. Ilag
Lyndon B. Lacaya
Tina M. Morwick
Ramón Ortiz Carrasquillo
Diabetes Therapy, 2019, 10 : 189 - 203
[34] Cost-effectiveness of biphasic insulin aspart 30 versus human premix insulin for type 2 diabetes patients in China
Lynch, M.
Scheijbeler, H.
Kotchie, R.
Neilsen, S.
White, J.
Valentine, W. J.
VALUE IN HEALTH, 2007, 10 (06) : A262 - A262
[35] Comparison of Thrice Daily Biphasic Human Insulin Versus Basal Detemir and Bolus Aspart in Patients with Poorly Controlled Type 2 Diabetes Mellitus.
Bhansali, Anil
Sanmugasundar, G.
Dutta, Pinaki
Sachdeva, Naresh
ENDOCRINE REVIEWS, 2010, 31 (03)
[36] Comparison of Insulin Degludec/Insulin Aspart and Biphasic Insulin Aspart 30 in Uncontrolled, Insulin-Treated Type 2 Diabetes: A Phase 3a, Randomized, Treat-to-Target Trial
Fulcher, Gregory R.
Christiansen, Jens Sandahl
Bantwal, Ganapathi
Polaszewska-Muszynska, Miroslawa
Mersebach, Henriette
Andersen, Thomas H.
Niskanen, Leo K.
DIABETES CARE, 2014, 37 (08) : 2084 - 2090
[37] Type 1 diabetes patients can temporarily switch from continuous subcutaneous insulin infusion with insulin aspart to basal bolus therapy with insulin aspart and insulin glargine.
Bode, BW
Hirsch, IB
Hu, P
Santiago, O
DIABETOLOGIA, 2003, 46 : A270 - A270
[38] Transferring patients with type 2 diabetes no longer controlled with basal human insulin to biphasic insulin aspart 30 leads to improved control
Barbonta, Diana H.
Mocan, Emiliana
Yeo, Jing Ping
DIABETES, 2008, 57 : A562 - A563
[39] Cost-effectiveness analysis of insulin therapy in type 2 diabetes patients comparing biphasic insulin aspart 70/30 versus insulin plargine in the Swedish setting
Ray, Joshua A.
Munro, Vicki
Brandt, Ann-Sofie
Valentine, William J.
Roze, Stephane
Foos, Volker
Lurati, Francesco
Palmer, Andrew J.
DIABETES, 2006, 55 : A558 - A558
[40] Intensification of insulin therapy in patients with type 2 diabetes mellitus: An algorithm for basal-bolus therapy
Abrahamson, Martin J.
Peters, Anne
ANNALS OF MEDICINE, 2012, 44 (08) : 836 - 846

← 1 2 3 4 5 →